Amoxicillin Regimen for Enterococcus faecalis UTI
For Enterococcus faecalis urinary tract infections, amoxicillin at a dose of 500-875 mg three times daily for 7 days is the recommended first-line treatment when susceptibility is confirmed. 1
Treatment Selection Algorithm
First-Line Options:
Amoxicillin: 500-875 mg orally three times daily for 7 days
- Preferred for susceptible E. faecalis strains
- High urinary concentrations make it effective even for some isolates with higher MICs 2
Amoxicillin-clavulanic acid: 500/125 mg orally three times daily for 7 days
Alternative Options (if amoxicillin resistance confirmed):
Nitrofurantoin: 100 mg orally twice daily for 5-7 days
Fosfomycin: 3 g single oral dose
Special Considerations
Severity-Based Approach:
- Uncomplicated lower UTI: Oral amoxicillin is appropriate
- Complicated UTI/Pyelonephritis: Consider parenteral therapy initially
- Ampicillin 2 g IV every 6 hours 3
- Switch to oral therapy when clinically improved
Resistance Patterns:
- E. faecalis generally remains susceptible to ampicillin/amoxicillin (unlike E. faecium) 6
- For ampicillin-resistant strains, consider:
Important Caveats:
- Do not use fluoroquinolones as empiric therapy for E. faecalis UTIs due to high resistance rates (47% resistance to ciprofloxacin reported) 6
- Avoid cephalosporins as enterococci are intrinsically resistant
- Distinguish colonization from infection before initiating therapy, especially in catheterized patients 5
- Remove indwelling catheters whenever possible to improve treatment outcomes 7
Monitoring and Follow-up
- Clinical response should be assessed within 48-72 hours
- Repeat urine culture only if symptoms persist after appropriate therapy
- Consider infectious disease consultation for vancomycin-resistant enterococci (VRE) 1
Duration of Therapy
- Uncomplicated lower UTI: 5-7 days
- Complicated UTI or pyelonephritis: 10-14 days
The high urinary concentrations of amoxicillin (exceeding serum levels by 10-100 times) make it particularly effective for treating E. faecalis UTIs, even when in vitro susceptibility testing suggests resistance based on serum breakpoints 2.